Literature DB >> 15911356

Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE).

Isaac G Onyango1, Jeremy B Tuttle, James P Bennett.   

Abstract

Activation of apoptosis by increased production of amyloid beta peptides (Abeta) has been implicated in neuronal cell death of Alzheimer's disease (AD). We used mitochondrial transgenic cybrid models of sporadic AD (SAD), which overproduce Abeta compared to control (CTL) cybrids, to investigate the effects of endogenously generated Abeta on intracellular signaling pathways and viability. Reducing SAD Abeta production with gamma-secretase inhibition altered the total phosphorylation profile of SAD cybrid to one similar to CTL cybrids and enhanced viability to approximately CTL cybrid levels. Treating CTL cybrids with exogenous Abeta or conditioned media (CM) from SAD cybrids activated the signaling pathways active in SAD cybrids under basal condition and decreased viability. Antibodies against receptor for advanced glycation end products (RAGE) blocked Abeta-induced activation of the p38, JNK pathways, and NF-kappaB in CTL cybrids and offered protection against the neurotoxic effects of Abeta. Expression of SAD mitochondrial genes in cybrids activates stress-related signaling pathways and reduces viability. This SAD phenotype is produced by endogenously generated Abeta and can be replicated by exogenous Abeta acting through RAGE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911356     DOI: 10.1016/j.mcn.2005.02.012

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  22 in total

1.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

2.  RAGE: the beneficial and deleterious effects by diverse mechanisms of actions.

Authors:  Sun-Ho Han; Yoon Hee Kim; Inhee Mook-Jung
Journal:  Mol Cells       Date:  2011-01-18       Impact factor: 5.034

3.  A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis.

Authors:  Lili Cui; Yujie Cai; Wanwen Cheng; Gen Liu; Jianghao Zhao; Hao Cao; Hua Tao; Yan Wang; Mingkang Yin; Tingting Liu; Yu Liu; Pengru Huang; Zhou Liu; Keshen Li; Bin Zhao
Journal:  Mol Neurobiol       Date:  2016-02-22       Impact factor: 5.590

4.  Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Nairita Roy; Lewis Hutfles; Jeffrey M Burns; Elias K Michaelis; ShiDu Yan; Sandra M Cardoso; Russell H Swerdlow
Journal:  Hum Mol Genet       Date:  2013-06-04       Impact factor: 6.150

Review 5.  Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-09-15       Impact factor: 8.401

6.  Association between the RAGE G82S polymorphism and Alzheimer's disease.

Authors:  Keshen Li; Dawei Dai; Bin Zhao; Lifen Yao; Songpo Yao; Binyou Wang; Ze Yang
Journal:  J Neural Transm (Vienna)       Date:  2009-11-10       Impact factor: 3.575

7.  RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction.

Authors:  Kazuhiro Takuma; Fang Fang; Wensheng Zhang; Shiqiang Yan; Emiko Fukuzaki; Heng Du; Alexander Sosunov; Guy McKhann; Yoko Funatsu; Noritaka Nakamichi; Taku Nagai; Hiroyuki Mizoguchi; Daisuke Ibi; Osamu Hori; Satoshi Ogawa; David M Stern; Kiyofumi Yamada; Shirley Shidu Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

Review 8.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009

10.  Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease.

Authors:  Michelle Y Wang; Fred N Ross-Cisneros; Divya Aggarwal; Chiao-Ying Liang; Alfredo A Sadun
Journal:  Acta Neuropathol       Date:  2009-03-11       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.